Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and…
PRAX-562 demonstrated robust preclinical antiseizure activity and exhibited an improved preclinical tolerability profile compared to standard-of-care Praxis expects to initiate a Phase 2 trial in the first half of 2022 to explore the…